Solvonis Therapeutics Plc (LSE:SVNS) has just bought itself more time. On 25 August 2026 the London-listed CNS drug developer raised £1.3m gross at 0.12p a share, a roughly 14% discount to the previous close, to push three addiction programmes towards their next milestones. The placing follows a £1.25m raise last October and £4.27m of Equity issuance in 2025, and it lands with the shares at a 52-week low.

The question is whether the pipeline can deliver a catalyst big enough to change the narrative before the next cheque is needed. Solvonis has a Phase 3 asset in severe alcohol use disorder, a US programme approaching an IND filing and a discovery compound funded by the US National Institute on Drug Abuse. It also has a going-concern warning in its latest accounts, no Revenue and a share count approaching 8 billion.

Latest development: £1.3m placing at 0.12p and a change of broker

The 25 August announcement detailed a placing of 1,083,333,333 new shares at £0.0012 each, raising £1.3m before expenses, about 14% below the 0.14p closing price the day before. Broker, adviser and Orana warrants over 133,333,333 shares were also granted. Turner Pope Investments replaced Singer Capital Markets as broker, and shares in issue rose to 7,899,736,826.

The proceeds will fund assessment of international sites for the SVN-001 Phase 3 study in severe alcohol use disorder (AUD), advance SVN-002 towards an IND submission and a US Phase 2b trial in moderate-to-severe AUD, and progress SVN-015 with the National Institute on Drug Abuse (NIDA) for stimulant use disorders. Chief executive Anthony Tennyson said the fundraising “supports clear next steps across our three priority programmes”.

The timing matters. In the FY2025 results on 29 April 2026, the board said year-end cash of £1.72m was “expected to provide funding through to end of 2026”, while acknowledging that going-concern status “is dependent on the successful completion of further equity fundraising within the assessment period”.

Business overview: a CNS pipeline built from the Awakn deal

Solvonis (LSE:SVNS) is a pre-revenue biopharmaceutical company focused on addiction and psychiatry. Formerly Graft Polymer (UK) plc, it changed its name and ticker on 15 January 2025 and completed the Acquisition of Canada’s Awakn Life Sciences in May 2025, recording £5.6m of intangible Assets and refocusing entirely on CNS drug development.

The lead asset, SVN-001, combines intravenous ketamine with cognitive behavioural therapy for severe AUD and is in a UK Phase 3 trial run by the University of Exeter Clinical Trials Unit across nine NHS trusts, co-funded by the Medical Research Council and the National Institute for Health and Care Research, with the company’s contribution capped at £800,000. The board is targeting the UK and Europe for commercialisation.

SVN-002 is a sublingual esketamine oral thin film for moderate-to-severe AUD aimed at the US, which the FDA confirmed in December 2024 can use the 505(b)(2) pathway, relying on data for the approved intranasal product Spravato. Behind these sit two discovery-stage compounds: SVN-114 for post-traumatic stress disorder and SVN-015, a serotonin and dopamine reuptake inhibitor for cocaine and methamphetamine use disorders.

FY2025 results: wider loss, Impairment and a going-concern note

For the year ended 31 December 2025, Solvonis reported nil revenue, unchanged from 2024. The operating loss widened to £3.477m from £1.383m, including a £2.263m impairment relating to the disposal of intellectual property. Loss before tax was £5.740m against £1.447m. Loss per share was 0.12p against 0.13p, on a weighted share count that rose to 4.865 billion from 1.157 billion.

Cash at 31 December 2025 was £1.720m, up from £0.757m, after £4.270m of gross share-issue proceeds during the year. Net assets rose to £6.191m from £3.084m, largely on the Awakn intangibles. No Dividend is paid. Interim results for the six months to 30 June 2026 are due by the end of September.

What could drive the stock next?

The nearest-term news flow is likely to come from SVN-002. On 22 June 2026 the company reported preclinical bridging data showing sublingual-buccal dosing produced esketamine exposure comparable to Spravato, which chief scientific officer Professor David Nutt called “very encouraging”. The next step is FDA feedback on the remaining toxicology package, then an IND submission. Awakn had originally planned an IND in the second half of 2025, so a filing would show the programme is back on track.

SVN-015 offers a lower-cost validation route. On 6 August 2026 NIDA agreed to fund further preclinical work after the compound showed a more favourable cardiac ion-channel profile than GBR-12909, an earlier dopamine transporter inhibitor. Tennyson called NIDA’s decision “important external validation”.

The largest prize remains SVN-001. Chairman Dennis Purcell has argued that “greater Shareholder value may be available at or following successful completion of Phase 3 than through an earlier transaction”, while retaining “flexibility around future strategic options”. A Phase 3 readout date, or a partnering deal, would be transformative relative to a Market Value of under £10m.

Risks investors should watch

Funding is the dominant risk for Solvonis (LSE: SVNS). The FY2025 accounts carry a material uncertainty over going concern, and £1.3m gross is small against an annual operating loss above £1.2m before impairment. Further dilution appears likely: shares in issue have grown to 7.9 billion, and the placing price has fallen from 0.33p in October 2025 to 0.12p in August 2026. Warrants over more than 133 million shares add to the overhang.

Clinical risk is high. Solvonis has not disclosed Phase 3 patient numbers or a readout date. SVN-002 still requires FDA agreement on toxicology before an IND can be filed, and the original timetable has already slipped. The discovery assets are years from the clinic.

The 52-week range of 0.122p to 0.395p, per lse.co.uk, shows how volatile a sub-penny stock can be. Water Tower Research, which initiated coverage on 13 July 2026, is paid by the company, so its peer comparisons are sponsored analysis.

Outlook

Solvonis Therapeutics enters the autumn with fresh cash, three programmes with defined next steps and a board intent on carrying SVN-001 through Phase 3 rather than selling early. The interim results due by the end of September should update the cash runway.

Beyond that, watch for FDA feedback on SVN-002 and an IND submission, NIDA data on SVN-015, and any disclosure on Phase 3 recruitment or timing. Each would strengthen the story; none removes the need for further capital. For a company valued at under £10m with a going-concern warning, the balance between clinical progress and dilution will decide whether the next catalyst changes the trajectory or simply funds the one after it.